Prevention of acute graft-vs.-host disease by targeting glycolysis and mTOR pathways in activated T cells. [PDF]
Exp Ther Med, 2022 Zhou RQ +10 more
europepmc +1 more source
Case report: Sudden onset optic neuritis shortly after SARS-CoV-2 vaccination in an allogeneic hematopoietic stem cell transplant recipient with chronic graft-vs.-host disease. [PDF]
Front Med (Lausanne), 2023 Chu C, Jiang SK, Shao YC, Yeh SP.
europepmc +1 more source
Severe Hypertriglyceridemia in a Patient Treated With Sirolimus for Graft-vs-Host Disease Prophylaxis. [PDF]
JCEM Case RepCriner K +4 more
europepmc +1 more source
Late follow-up of genital and ophthalmologic chronic graft-vs-host disease in females after allogeneic stem cell transplantation. [PDF]
Acta Obstet Gynecol Scand, 2022 Smith Knutsson E +5 more
europepmc +1 more source
International Journal of Cancer, EarlyView.Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim +22 more
wiley +1 more source
Case Report: Diagnosis and successful treatment of a rare case of steroid-refractory chronic graft-vs-host disease-related serositis. [PDF]
Front ImmunolXiong Z, Wang Z, Chen X.
europepmc +1 more source
IFN-γ and PPARδ influence the efficacy and retention of multipotent adult progenitor cells in graft vs host disease. [PDF]
Stem Cells Transl Med, 2021 Carty F +6 more
europepmc +1 more source
Transfusion-Associated Graft-vs-Host Disease [PDF]
American Journal of Clinical Pathology, 2000 Timothy E. Gorman +7 more
openaire +1 more source